Regorafenib-d3

• UNSPSC Description:

  Regorafenib-d3 is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].

• Target Antigen:

  Autophagy; PDGFR; Raf; RET; VEGFR

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  98.0

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=NC=CC(OC2=CC=C(NC(NC3=CC=C(Cl)C(C(F)(F)F)=C3)=O)C(F)=C2)=C1)NC([2H])([2H])[2H]

• Molecular Weight:

  485.83

• References & Citations:

  [1]Wilhelm SM, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129(1), 245-255.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1255386-16-3